ArticleScientific reports2025
Quantitative microvessel orientation biomarkers derived from contrast free ultrasound imaging for cancer diagnosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Microvessel orientations are known to differ between benign and malignant tumors. This article introduces novel orientation-based quantitative biomarkers for contrast-free ultrasound microvasculature imaging to distinguish malignant from benign breast lesions. The proposed biomarkers were computed in both polar and Cartesian coordinates using images acquired by a high-definition microvasculature imaging technique. Seven biomarkers were derived based on the histogram, gradient angle, angle of penetration, and penetration factor of the microvessel. These biomarkers are first evaluated using simulated microvessel images and subsequently validated in in vivo studies on human breast masses. The new biomarkers demonstrated statistical significance in differentiating benign from malignant breast masses. In the in vivo study, the area under the receiver operating characteristic curve (AUC) for the proposed biomarkers was 0.91 (95% confidence interval [CI]: 0.86, 0.97). When the Breast Imaging Reporting and Data System (BI-RADS) score was included in the classification model, the AUC improved to 0.97 (95% CI: 0.91,1.00). These orientation-based biomarkers show promise in enhancing the diagnostic performance of ultrasound for classification of breast masses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.